» Articles » PMID: 26082776

Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?

Overview
Journal Front Immunol
Date 2015 Jun 18
PMID 26082776
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Tumors can escape immune destruction through the development of antigen loss variants and loss of antigen processing/presentation pathways, thereby rendering them invisible to T cells. Alternatively, mechanisms of peripheral T-cell tolerance that would normally be important for protection from the development of autoimmunity may also be co-opted to (i) generate an immuno-inhibitory tumor environment, (ii) promote development of regulatory cell populations, or (iii) cell-intrinsically inactivate tumor-specific T cells. Emerging evidence suggests that T-cell function is impaired in hematological malignancies, which may manifest from cognate interactions between T cells and the tumor. The immunological synapse forms the cognate T-cell and antigen-presenting cell interaction and is the site where key signalling events, including those delivered by co-inhibitory receptors, that determine the fate of T cells occur. Here, we review evidence that events at the immune synapse between T cells and malignant B cells and alterations in immune synapse function may contribute to loss of T-cell function in B-cell malignancies.

Citing Articles

The long-term risk of immune-related conditions in survivors of diffuse large B-cell lymphoma: A Danish nationwide registry study.

Pedersen L, Klausen N, Jensen J, Bacevicius E, Brown P, Jorgensen J EJHaem. 2025; 6(1):e1070.

PMID: 39866948 PMC: 11756995. DOI: 10.1002/jha2.1070.


mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review.

Boretti A Clin Exp Med. 2024; 24(1):23.

PMID: 38280109 PMC: 10821957. DOI: 10.1007/s10238-023-01264-1.


Canine diffuse large b-cell lymphoma downregulates the activity of CD8 + T-cells through tumor-derived extracellular vesicles.

Weng H, Ke C, Tung C, Tani A, Wang C, Yang W Cancer Cell Int. 2023; 23(1):252.

PMID: 37884996 PMC: 10601183. DOI: 10.1186/s12935-023-03104-4.


PD-L1 Is Involved in the Development of Non-Hodgkin's Lymphoma by Mediating Circulating Lymphocyte Apoptosis.

Saber M Vaccines (Basel). 2023; 11(9).

PMID: 37766150 PMC: 10538143. DOI: 10.3390/vaccines11091474.


Junction of the redox dynamic, orchestra of signaling, and altered metabolism in regulation of T- cell lymphoma.

Singh S, Maurya A Front Oncol. 2023; 13:1108729.

PMID: 37274286 PMC: 10235457. DOI: 10.3389/fonc.2023.1108729.


References
1.
Prato S, Zhan Y, Mintern J, Villadangos J . Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold. J Immunol. 2013; 191(7):3534-44. DOI: 10.4049/jimmunol.1300803. View

2.
Ahmadzadeh M, Johnson L, Heemskerk B, Wunderlich J, Dudley M, White D . Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8):1537-44. PMC: 2927090. DOI: 10.1182/blood-2008-12-195792. View

3.
Vardhana S, Choudhuri K, Varma R, Dustin M . Essential role of ubiquitin and TSG101 protein in formation and function of the central supramolecular activation cluster. Immunity. 2010; 32(4):531-40. PMC: 2905630. DOI: 10.1016/j.immuni.2010.04.005. View

4.
Green M, Monti S, Rodig S, Juszczynski P, Currie T, ODonnell E . Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116(17):3268-77. PMC: 2995356. DOI: 10.1182/blood-2010-05-282780. View

5.
Bennett S, Carbone F, Toy T, Miller J, Heath W . B cells directly tolerize CD8(+) T cells. J Exp Med. 1998; 188(11):1977-83. PMC: 2212383. DOI: 10.1084/jem.188.11.1977. View